News about Market

AstraZeneca Boosts Weight Management Portfolio via CSPC Collaboration

Under this agreement, Astrazeneca and CSPC Pharmaceuticals will initially progress four programmes, which utilise CSPC's advanced Artificial Intelligence (AI)-driven peptide drug discovery platform and their proprietary LiquidGel once-monthly dosing platform technology.

Market | 31/01/2026 | By News Bureau |  335

Mabtech and Sai Life Sciences Partner to Advance Immunology Research

Under this collaboration, Mabtech and Sai will jointly deliver advanced immunology assay services — including high-sensitivity multiplex cytokine and phenotyping workflows — powered by the EYRA platform installed at Sai’s Boston discovery site.

Market | 31/01/2026 | By News Bureau |  195

Concerto and Sacco System Sign Microbial Discovery Deal

Concerto and Sacco System aim to develop novel ingredients composed of synergistically interacting microbes with desirable functional properties.

Market | 30/01/2026 | By News Bureau |  147

AstraZeneca Commits USD 15 Billion to Expand Manufacturing and R&D in China

UK-based pharmaceutical major AstraZeneca has announced a USD 15 billion investment in China by 2030, marking its largest-ever commitment to the country. The investment is aimed at expanding the company’s research, development and manufacturing capabilities, reinforcing China’s role as a key pillar in AstraZeneca’s global growth strategy.

Market | 30/01/2026 | By Darshana |  157

Evestia Clinical Expands European Footprint with Acquisition of ICRC-Weyer

Evestia Clinical, a global independent specialist contract research organization (CRO), has announced the acquisition of Berlin-based ICRC-Weyer GmbH, a long-established CRO and scientific consultancy with strong expertise in data-driven clinical research.

Market | 29/01/2026 | By Darshana |  160

WuXi Biologics, Sinorda Biomedicine Partner to Advance Bispecific Antibody for Autoimmune Diseases

WuXi Biologics and Sinorda Biomedicine collaborate to accelerate development of SND006, a novel bispecific antibody targeting inflammatory bowel disease and autoimmune disorders.

Market | 29/01/2026 | By News Bureau |  264

Boehringer and Simcere Partner on Dual-Target IBD Antibody

Boehringer Ingelheim has signed a licence and collaboration deal with Simcere to develop a novel TL1A/IL23p19 bispecific antibody for inflammatory bowel disease, gaining global rights outside greater China, with Simcere eligible for up to €1.058 billion in payments.

Market | 29/01/2026 | By News Bureau |  181

Davaindia Launches 77 New Stores Nationwide to Mark India's 77th Republic Day

The expansion by Zota Healthcare’s generic pharmacy chain strengthens access to affordable medicines across metros and Tier II and III cities under its “Har Ghar Ki Pharmacy” vision.

Market | 28/01/2026 | By News Bureau |  536

India's OTC Market Projected to Reach INR 98,000 Crore by 2030, EY Report Says

A new report by EY projects that India’s over-the-counter (OTC) drug market is expected to nearly double by 2030, reaching INR 98,000 crore, up from around INR 47,000 crore in 2024, growing at a compound annual growth rate of about 13 per cent.

Market | 28/01/2026 | By Darshana |  384

Insilico Medicine and Qilu Pharmaceutical Sign USD 120 Million Cardiometabolic Drug Deal

According to the agreement, Insilico Medicine will utilise its proprietary Pharma.AI platform to focus on the design and optimisation of novel small molecules for treating metabolic diseases, while Qilu Pharmaceutical Group will be responsible for subsequent development and commercialisation procedures.

Market | 28/01/2026 | By News Bureau |  218